CTLA4 and telomere syndrome: We hypothesize that the riskscore can effectively predict patient responses to immunotherapy, such as anti-PD-1/PD-L1 and anti-CTLA-4 treatments, with the low-risk group being more likely to benefit from immune checkpoint inhibitor therapy in STS.